Navigation Links
Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
Date:2/4/2008

TUCSON, Ariz., Feb. 4 /PRNewswire/ -- Aung FootHealth Clinics & Advanced Wound Care Center today announced it is recruiting patients with lower extremity diabetic foot ulcers to participate in the MATRIX clinical trial. The MATRIX trial will study the effects of Excellarate(TM) (GAM501) (Ad5PDGF-B/bovine Type I collagen gel) for the potential treatment of patients with neuropathic non-healing diabetic foot ulcers. Excellarate is an investigational product designed to stimulate the process of wound healing.

The MATRIX (A Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers in the Lower Extremities) trial is a randomized, double-blind, placebo-controlled, comparator arm (standard of care) safety and efficacy study to evaluate GAM501 (Ad5PDGF-B/bovine type I collagen gel) that is topically administered once or twice over the course of the study. The primary endpoint will be the effect of Excellarate on the incidence of complete ulcer closure at 12 weeks or earlier.

"The Excellarate topical gel using Gene Activated Matrix (GAM) technology is designed to provide localized and sustained cellular release of platelet-derived growth factor-BB protein (PDGF-BB). Sustained delivery of PDGF-BB directly at the wound site is believed to stimulate angiogenesis and granulation tissue formation through the recruitment and proliferation of chemotactic cells such as monocytes, fibroblasts, and endothelial cells, which are necessary for the stimulation of a variety of wound healing processes," stated Barbara J. Aung, DPM, CWS Aung FootHealth Clinics & Advanced Wound Care Center, and a trial investigator.

There are currently more than 20 million Americans who have diabetes and this number is expected to double by the year 2030. Many diabetic patients suffer from peripheral neuropathy, or a loss of feeling in their feet, that puts them at increased risk of foot ulceration. Over 850,000 chronic diabetic ulcers are diagnosed in the U.S. each year. Patients with non-healing ulcers are more susceptible to infections that may lead to amputation of the affected foot or leg.

Aung FootHealth Clinics & Advanced Wound Care Center is among an estimated 25 sites participating in the MATRIX trial. The trial is expected to enroll 210 patients nationwide. Prospective participants can call Aung FootHealth Clinics & Advanced Wound Care Center at (520) 886-9866 for more information about the study and eligibility.

For over 15 years Barbara J. Aung, DPM, CWS and Aung FootHealth Clinics & Advanced Wound Care Center has been a leader in the field of Podiatric Medicine specializing in Advanced Wound Care, Limb Preservation and Amputation Prevention. Most chronic/long standing wounds that are treated in our wound care center heal within 8-12 weeks. In fact, over 95% of the wounds that are treated heal fully. Using proven clinical pathways, our specifically trained staff provides comprehensive individualized treatment to patients.

Please visit our website at http://www.healthy-feet.com for additional information on "Keeping your Feet Healthy for the Journeys...Yet to be Made."


'/>"/>
SOURCE Aung FootHealth Clinics & Advanced Wound Care Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
2. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
6. Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio
7. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
8. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
9. Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkins Lymphoma
10. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
11. New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... , April 27, 2016 Tie-up ... initiative to save newborns   ... women & newborns in collaboration with Breast Milk Foundation (BMF), ... first Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This ... food source for infants and should be available to babies ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... reach over USD 2.14 billion by 2022, according ... Inc.       (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... technological advancement affecting the efficiency and accuracy delivered ... the persistent demand for novel urinalysis instruments and ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... 2016 , ... Cosmetic Town, an online plastic surgery community, announces the relaunch ... recently revamped and upgraded to allow even more interaction between doctors and patients as ... According to the senior editor of Cosmetic Town, “We are excited that our ...
(Date:4/28/2016)... ... April 28, 2016 , ... Greener Hydroponics is now ... pots are frequently used by professional organic farmers and nurseries according to Sales Manager ... supply of fabric pots. Our goal is to offer wholesale level pricing and ultra-fast ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine named Herr the ... of biomechatronics, technology that marries human physiology with electromechanics. He continues that work as ... the Founder of BionX , a leader in the field of prosthetic devices. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... of enterprise Data Center Infrastructure Management solutions, announces today the availability of ... enhancements in the area of capacity management and optimization, providing new analytical ...
(Date:4/28/2016)... ... April 28, 2016 , ... One way to ignore solid evidence is ... true. But we toss the baby out with the bathwater when we ignore all ... identifying higher-quality studies and otherwise making better use of education policy research. , “When ...
Breaking Medicine News(10 mins):